Organon & Co earnings were $501.0M for the trailing 12 months ending Sep 30, 2025, with -61.9% growth year over year. The latest OGN earnings report on Sep 30, 2025 announced Q3 2025 earnings of $160.0M, up 10.3% from last quarter. For the last reported fiscal year 2024 ending Dec 31, 2024, OGN reported annual earnings of $864.0M, with -15.5% growth.
OGN past earnings growth
How has OGN's earnings growth performed historically?
On OGN's earnings call on Invalid Date, Organon & Co (NYSE: OGN) reported Q3 2025 earnings per share (EPS) of $0.61, up 56.12% year over year. Total OGN earnings for the quarter were $160.00 million. In the same quarter last year, Organon & Co's earnings per share (EPS) was $1.39.
As of the last Organon & Co earnings report, Organon & Co is currently profitable. Organon & Co's net profit (also called net income) for the twelve months ending Sep 30, 2025 was $501.00 million, a 61.49% decrease year over year.
What was OGN's earnings growth in the past year?
As of Organon & Co's earnings date in Invalid Date, Organon & Co's earnings has grown -61.93% year over year. This is 406.01 percentage points lower than the US Drug Manufacturers - General industry earnings growth rate of 344.07%. OGN earnings in the past year totalled $501.00 million.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.